TABLE 3.
Sensitivity analyses of reporting risks for AKI upon the use of drugs prescribed for COVID-19 in DM.
| Remdesivir | Tocilizumab | Hydroxychloroquine | ||||
|---|---|---|---|---|---|---|
| Cases | ROR (95%CI) | Cases | ROR (95%CI) | Cases | ROR (95%CI) | |
| Model 1 | 90 | 9.20 (5.87–14.42)* | 4 | 1.39 (0.49–3.95) | 4 | 0.89 (0.32–2.49) |
| Model 2 | 102 | 5.47 (3.90–7.66)* | 10 | 2.31 (1.15–4.62)* | 8 | 1.16 (0.55–2.44) |
| Model 3 | 86 | 8.12 (5.09–12.95)* | 5 | 1.44 (0.56–3.71) | 8 | 1.89 (0.88–4.08) |
| Model 4 | 101 | 6.76 (4.59–9.96)* | 9 | 2.42 (1.16–5.05)* | 5 | 0.83 (0.33–2.10) |
| Model 5 | 62 | 5.07 (3.38–7.62)* | 5 | 2.58 (0.99–6.74) | 8 | 1.81 (0.85–3.85) |
The asterisk indicates statistical significance.
AKI: acute kidney injury; DM: diabetes mellitus; ROR: reporting odds ratio; CI: confidence interval.
Model 1: excluding hypertensive reports.
Model 2: restricted to reports with severe outcomes of an event.
Model 3: excluding reports listing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).
Model 4: excluding reports listing dipeptidyl peptidase 4 (DPP4) inhibitors.
Model 5: excluding reports listing known nephrotoxic drugs (vancomycin, bumetanide, chlorothiazide, spironolactone, hydrochlorothiazide, aciclovir, amikacin, amphotericin b, chlortalidone, nimesulide).